The PE is rich in the mid-50s, but has 20% revenue growth, and they have a revolutionary medical device, an insulin patch. Have a new CEO.
Stock price when the opinion was issued
Build your watch list
Sign in to track investmentsyou care about
ReSolve Asset Management
5i Research
Stockchase Premium
CNBC
Stockchase
The PE is rich in the mid-50s, but has 20% revenue growth, and they have a revolutionary medical device, an insulin patch. Have a new CEO.